نتایج جستجو برای: pyrimidinone

تعداد نتایج: 226  

Journal: :Molecular pharmacology 2016
Justin A MacDonald Cindy Sutherland David A Carlson Sabreena Bhaidani Abdulhameed Al-Ghabkari Karl Swärd Timothy A J Haystead Michael P Walsh

A novel inhibitor of zipper-interacting protein kinase (ZIPK) was used to examine the involvement of ZIPK in the regulation of smooth muscle contraction. Pretreatment of de-endothelialized rat caudal arterial smooth muscle strips with the pyrazolo[3,4-d]pyrimidinone inhibitor 2-((1-(3-chlorophenyl)-4-oxo-4,5-dihydro-1H-pyrazolo [3,4-d]-pyrimidin-6-yl)thio)propanamide (HS38) decreased the veloci...

2014
Majid Ghashang Syed Sheik Mansoor Krishnamoorthy Aswin

A new, simple thermally efficient and solvent-free condensation of 2-amino-3-cyano-6-methyl-4-phenyl-4H-pyran-5-ethylcarboxylate derivatives with coumarin-3-carboxylic acid employing pentafluorophenylammonium triflate (PFPAT) as an inexpensive organocatalyst for the synthesis of a series of ethyl 4,5-dihydro 7-methyl-2-(2-oxo-2H-chromen-3-yl)-4-oxo-5-aryl-3H-chromeno[2,3-d]pyrimidine-6-carboxyl...

Journal: :Biomaterials 2006
Patricia Y W Dankers Ellen N M van Leeuwen Gaby M L van Gemert A J H Spiering Martin C Harmsen Linda A Brouwer Henk M Janssen Anton W Bosman Marja J A van Luyn E W Meijer

We show that materials with a diverse range of mechanical and biological properties can be obtained using a modular approach by simply mixing different ratios of oligocaprolactones that are either end-functionalized or chain-extended with quadruple hydrogen bonding ureido-pyrimidinone (UPy) moieties. The use of two UPy-synthons allows for easy synthesis of UPy-modified polymers resulting in hig...

Journal: :The Journal of pharmacology and experimental therapeutics 2005
Mark D Erion Paul D van Poelje Deidre A Mackenna Timothy J Colby Annika C Montag James M Fujitaki David L Linemeyer David A Bullough

Targeting drugs to specific organs, tissues, or cells is an attractive strategy for enhancing drug efficacy and reducing side effects. Drug carriers such as antibodies, natural and manmade polymers, and labeled liposomes are capable of targeting drugs to blood vessels of individual tissues but often fail to deliver drugs to extravascular sites. An alternative strategy is to use low molecular we...

Journal: :The Journal of pharmacology and experimental therapeutics 2012
Alexander R Ochman Christopher A Lipinski Jeffrey A Handler Andrew G Reaume Michael S Saporito

MLR-1023 [Tolimidone; CP-26154; 2(1H)-pyrimidinone, 5-(3-methylphenoxy)] is an allosteric Lyn kinase activator that reduces blood glucose levels in mice subjected to an oral glucose tolerance test (J Pharmacol Exp Ther 342:15-22, 2012). The current studies were designed to define the role of insulin in MLR-1023-mediated blood glucose lowering, to evaluate it in animal models of type 2 diabetes,...

Journal: :Cancer research 1985
L H Li T L Wallace K A Richard D E Tracey

This study was undertaken in an attempt to understand the mechanism of antitumor action of pyrimidinones alone and in combination with cyclophosphamide (CY). Pyrimidinones such as 2-amino-5-bromo-6-(3-fluorophenyl)-4(3H)pyrimidinone (ABMFPP) were relatively nontoxic toward murine L1210 leukemia cell growth in vitro with the concentration of drug required for a 50% inhibition of cell growth bein...

2012
Michael S. Saporito Alexander R. Ochman Christopher A. Lipinski Jeffrey A. Handler Andrew G. Reaume

MLR-1023 (2(1H)-Pyrimidinone, 5-(3-methylphenoxy)) is a candidate for the treatment of type 2 diabetes. The current studies were aimed at determining the mechanism by which MLR-1023 mediates glycemic control. In these studies, we showed that MLR1023 reduced blood glucose levels without increasing insulin secretion in vivo. We have further determined that MLR-1023 did not activate PPARα, δ, γ re...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید